medRxiv preprint doi: https://doi.org/10.1101/2021.06.21.21259262; this version posted June 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . The tumor suppressor Adenomatous polyposis coli modulates T lymphocyte migration Marta Mastrogiovanni1,2, Pablo Vargas3,4, Thierry Rose1, Celine Cuche1, Marie Juzans1, Elric Esposito5, Hélène Laude6, Charlotte Renaudat6, Marie-Noëlle Ungeheuer6, Jérôme Delon7, Andrés Alcover1*, Vincenzo Di Bartolo1*. 1 Lymphocyte Cell Biology Unit, Department of Immunology, Institut Pasteur, INSERM-U1224. Ligue Nationale Contre le Cancer, Équipe Labellisée Ligue 2018. F-75015 Paris, France. 2 Sorbonne Université, Collège Doctoral, F-75005 Paris. France. 3 Institut Curie, PSL Research University, CNRS, UMR 144, F-75005 Paris, France. 4 Institut Pierre-Gilles de Gennes, PSL Research University. F-75005 Paris, France. 5 UTechS Photonic BioImaging, Center for Technological Resources and Research, Institut Pasteur, 75015 Paris, France. 6 ICAReB, Institut Pasteur. F-75015 Paris. France. 7 Université de Paris, Institut Cochin, Inserm, CNRS, F-75014 Paris, France. * Correspondence to: Andrés Alcover, Department of Immunology, Institut Pasteur, 25-28 rue Docteur Roux, 75015 Paris; e-mail:
[email protected]; Tel: (+33)1 40 61 30 64; and Vincenzo Di Bartolo, Department of Immunology, Institut Pasteur, 25-28 rue Docteur Roux, 75015 Paris; e-mail:
[email protected]. Tel: (+33)1 40 61 36 55 Abstract Adenomatous polyposis coli (APC) is a tumor suppressor whose mutations underlie familial adenomatous polyposis (FAP) and colorectal cancer.